Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
LGN
LGN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LGN News
2025 IPO Class: 3 Stocks Showing Positive Chart Trends
Jan 23 2026
Barron's
Legence Corp. Upsizes Secondary Offering to 9.66 Million Shares at $45 Each
Jan 08 2026
Yahoo Finance
Legence Completes $325 Million Acquisition of Bowers Group
Jan 02 2026
Globenewswire
Legence Completes $325 Million Acquisition of Bowers Group
Jan 02 2026
Yahoo Finance
Legence Prices Upsized Secondary Offering of 8.4M Shares at $45 Each
Dec 12 2025
Globenewswire
Legence Prices Upsized Secondary Offering of 8.4M Shares at $45 Each
Dec 12 2025
Newsfilter
Legence Corp. to Offer 7 Million Shares in Secondary Public Offering
Dec 09 2025
Globenewswire
Legence (LGN) Price Target Raised by 13.60% to 46.70
Dec 07 2025
NASDAQ.COM
IMD Acquired by Legence Corp, Achieving 70% CAGR Over 4 Years
Dec 02 2025
PRnewswire
Tigress Financial Begins Coverage of Legence with a Buy Rating and Sets Price Target at $54
Nov 21 2025
Benzinga
Alphabet Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Tuesday
Nov 18 2025
Benzinga
Analysts Raise Their Projections for Legence Following Q3 Earnings Report
Nov 17 2025
Benzinga
Barclays Keeps Equal-Weight Rating on Legence and Increases Price Target to $37
Nov 17 2025
Benzinga
Goldman Sachs Reaffirms Buy Rating on Legence, Increases Price Target to $46
Nov 17 2025
Benzinga
BMO Capital Reaffirms Outperform Rating for Legence and Increases Price Target to $46
Nov 17 2025
Benzinga
Major Stocks Including Legence, Cidara Therapeutics, Avadel Pharmaceuticals, and Omeros Rise on Friday
Nov 14 2025
Benzinga
Show More News
